Prognostic value of lymph node metastases after neoadjuvant chemotherapy for large-sized operable carcinoma of the breast

C. Botti, P. Vici, M. Lopez, A. F. Scinto, F. Cognetti, R. Cavaliere

Research output: Contribution to journalArticlepeer-review

Abstract

BACKGROUND: Neoadjuvant chemotherapy followed by surgery or radiation therapy, or both, has become the treatment of choice for patients with large- sized resectable carcinoma of the breast in whom mastectomy is the conventional option. Since tumor regression before surgery is considered a favorable prognostic factor, there is still controversy regarding the need to perform an axillary dissection after a good response to systemic induction treatment. STUDY DESIGN: Between February 1990 and December 1993, we conducted a prospective study of 56 consecutive patients receiving high-dose anthracycline-based preoperative chemotherapy for large but potentially resectable carcinoma of the breast. Patients who had a good clinical response to induction systemic treatment received the same chemotherapy in the adjuvant phase, while those whose response was less than optimal received alternative adjuvant chemotherapy regimens. A multivariate analysis was made to evaluate the relative influence on disease-free survival rates of 11 clinicopathologic and treatment-related variables, including clinical response to primary chemotherapy, primary pathological (p-T) staging, and the number of metastatic lymph nodes. RESULTS: At a median follow-up period of 36 months, only the number of metastatic lymph nodes was found to be an independent predictor of relapse. Clinical response to systemic induction treatment and p-T staging did not correlate with prognosis. In the group of patients with axillary lymph node involvement, those who did not respond to preoperative chemotherapy showed a lower relapse rate compared with those who achieved an objective response. CONCLUSIONS: These findings suggest that axillary lymphadenectomy should be considered an important component of the combined modality therapy for patients with large-sized resectable carcinoma of the breast in order to identify subgroups of patients that may benefit from alternative treatments in the adjuvant setting.

Original languageEnglish
Pages (from-to)202-208
Number of pages7
JournalJournal of the American College of Surgeons
Volume181
Issue number3
Publication statusPublished - 1995

ASJC Scopus subject areas

  • Surgery

Fingerprint Dive into the research topics of 'Prognostic value of lymph node metastases after neoadjuvant chemotherapy for large-sized operable carcinoma of the breast'. Together they form a unique fingerprint.

Cite this